miR-342 targets CXC motif chemokine 12 (CXCL12), disrupting the CXCL12/CXC chemokine receptor type 4 (CXCR4) loop that sustains β-catenin activity in the tumor microenvironment, thus suppressing proliferation and enhancing apoptosis [55]. This evidence concerns the gene CXCL12 and neoplasm.